RANTES Antibody (VL1): sc-32246

RANTES Antibody (VL1) is a mouse monoclonal IgG2b antibody that detects RANTES in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). RANTES, also known as regulated upon activation, normal T cell expressed and secreted, plays a crucial role in the immune response by acting as a potent chemoattractant for various immune cells, including monocytes and natural killer cells. RANTES is primarily expressed by platelets, eosinophils, fibroblasts, macrophages, endothelial cells, and T lymphocytes, highlighting RANTES′s importance in mediating inflammatory responses and recruiting immune cells to sites of infection or injury. Notably, RANTES is characterized by a unique structure that includes a set of conserved cysteine residues, which are essential for stability and function. The presence of these cysteines allows for the formation of disulfide bonds, contributing to RANTES′s three-dimensional conformation and ability to interact with specific receptors on target cells. Understanding the structural features of RANTES is vital, as these features directly influence activity and role in various physiological and pathological processes, including chronic inflammation and immune regulation. Anti-RANTES antibody (VL1) is an invaluable tool for researchers studying the dynamics of immune responses and the underlying mechanisms of diseases associated with dysregulated chemokine activity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RANTES Antibody (VL1) References:

1. Cytokines, chemokines, RANTES, and eotaxin.  |  Graziano, FM., et al. 1999. Allergy Asthma Proc. 20: 141-6. PMID: 10389546
2. Transcriptional regulation of RANTES expression in T lymphocytes.  |  Song, A., et al. 2000. Immunol Rev. 177: 236-45. PMID: 11138780
3. MCP-1 and RANTES are mediators of acute and chronic inflammation.  |  Conti, P. and DiGioacchino, M. 2001. Allergy Asthma Proc. 22: 133-7. PMID: 11424873
4. RANTES deficiency attenuates autoantibody-induced glomerulonephritis.  |  Xie, C., et al. 2011. J Clin Immunol. 31: 128-35. PMID: 20886281
5. Angiogenic properties of the chemokine RANTES/CCL5.  |  Suffee, N., et al. 2011. Biochem Soc Trans. 39: 1649-53. PMID: 22103502
6. Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer.  |  Ang, L., et al. 2022. Bioengineering (Basel). 9: PMID: 35892755
7. RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration.  |  Fonteh, CN., et al. 2023. Transl Vis Sci Technol. 12: 19. PMID: 36633873
8. Elevated RANTES levels are associated with increased risk of cerebral atherosclerotic stenosis.  |  Guo, Y., et al. 2023. BMC Neurol. 23: 39. PMID: 36698075
9. The Potential Role of RANTES in Post-Stroke Therapy.  |  Pawluk, H., et al. 2023. Cells. 12: PMID: 37759440
10. STING/RANTES pathway in airway epithelium enhances Der p1-induced airway inflammation.  |  Tsuji, M., et al. 2024. Allergy. 79: 2008-2011. PMID: 38837714

The preferred RANTES antibody is RANTES Antibody (A-4): sc-365826.